{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T05:15:26Z","timestamp":1739855726612,"version":"3.37.3"},"reference-count":3,"publisher":"American College of Physicians","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.acpjournals.org\/journal\/aim\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Intern Med"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.7326\/annals-24-02768-jc","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T22:00:31Z","timestamp":1730757631000},"page":"JC127","source":"Crossref","is-referenced-by-count":0,"title":["In active ulcerative colitis, risankizumab induced and maintained remission"],"prefix":"10.7326","volume":"177","author":[{"given":"Alessandro","family":"Pedicelli","sequence":"first","affiliation":[{"name":"McGill University, Montreal, Quebec, Canada (A.P., W.A.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6869-0982","authenticated-orcid":false,"given":"Waqqas","family":"Afif","sequence":"additional","affiliation":[{"name":"McGill University, Montreal, Quebec, Canada (A.P., W.A.)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4285","reference":[{"key":"ANNALS-24-02768-R1","doi-asserted-by":"crossref","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, et al; LUCENT Study Group. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388:2444-2455. [PMID: 37379135]","DOI":"10.1056\/NEJMoa2207940"},{"key":"ANNALS-24-02768-R2","doi-asserted-by":"crossref","unstructured":"Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al; VARSITY Study Group. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381:1215-1226. [PMID: 31553834]","DOI":"10.1056\/NEJMoa1905725"},{"key":"ANNALS-24-02768-R3","doi-asserted-by":"crossref","unstructured":"Peyrin-Biroulet L, Chapman JC, Colombel JF, et al; SEQUENCE Study Group. Risankizumab versus ustekinumab for moderate-to-severe Crohn's disease. N Engl J Med. 2024;391:213-223. [PMID: 39018531]","DOI":"10.1056\/NEJMoa2314585"}],"container-title":["Annals of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.acpjournals.org\/doi\/pdf\/10.7326\/ANNALS-24-02768-JC","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.acpjournals.org\/doi\/full-xml\/10.7326\/ANNALS-24-02768-JC","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T22:02:27Z","timestamp":1739829747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.acpjournals.org\/doi\/10.7326\/ANNALS-24-02768-JC"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":3,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.7326\/ANNALS-24-02768-JC"],"URL":"https:\/\/doi.org\/10.7326\/annals-24-02768-jc","relation":{},"ISSN":["0003-4819","1539-3704"],"issn-type":[{"type":"print","value":"0003-4819"},{"type":"electronic","value":"1539-3704"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}